Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Biomarkers for Predicting the Outcome of Various Cancer Immunotherapies Publisher Pubmed



Jafarzadeh L1 ; Khakpoorkoosheh M1 ; Mirzaei H2 ; Mirzaei HR1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran

Source: Critical Reviews in Oncology/Hematology Published:2021


Abstract

Cancer immunotherapy has appeared as a well-known therapeutic modality for different cancers. Yet, only a subset of patients derive clinical benefit. It is thus critical to understand the determinants driving response, resistance and adverse effects.Predictive biomarkers in different modalities of cancer immunotherapy offer novel information about the effect of a therapeutic intervention. These biomarkers and their patterns may not only operate similarly across different tumor types that are amenable to these therapies but also assist to identify patients who will benefit from the treatment and subsequently leading to tailored immunotherapy with the wider-successfully-targeted patient population. In this review, we will outline a variety of predictive biomarkers in various cancer immunotherapies and their clinical utility. It is anticipated that the incorporation of biomarker studies in the clinical practice will help optimize therapeutic decision making and realize the potential clinical benefit of biomarker-guided therapy. © 2020 Elsevier B.V.
Related Docs
View other Related Docs
1. Tumor Immunology, Clinical Immunology (2022)
2. Biomarkers for Immune Checkpoint Inhibitors, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
3. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)
4. Pd-1/Pd-L1 Pathway: Basic Biology and Role in Cancer Immunotherapy, Journal of Cellular Physiology (2019)
5. Resistance to Immunotherapy in Human Malignancies: Mechanisms, Research Progresses, Challenges, and Opportunities, Journal of Cellular Physiology (2022)
6. Predictive and Therapeutic Biomarkers in Chimeric Antigen Receptor T-Cell Therapy: A Clinical Perspective, Journal of Cellular Physiology (2019)
7. Review of the Recent Clinical Trials for Pd-1/Pd-L1 Based Lung Cancer Immunotherapy, Expert Review of Anticancer Therapy (2021)
8. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (45)
Hamid Reza Mirzaei (16)
Other Related Docs
9. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
10. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
11. The Evolving Landscape of Predictive Biomarkers in Immuno-Oncology With a Focus on Spatial Technologies, Clinical and Translational Immunology (2020)
12. Immunotherapeutic Targets in Non-Small Cell Lung Cancer, Immunology (2023)
13. Resistance Mechanisms to Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Inhibitors, Expert Opinion on Biological Therapy (2021)
14. Understanding the Tumor Microenvironment for Effective Immunotherapy, Medicinal Research Reviews (2021)
15. Recent Progress in Cancer Immunotherapy: Overview of Current Status and Challenges, Pathology Research and Practice (2023)
16. Recent Advances in Immune Checkpoint Therapy in Non-Small Cell Lung Cancer and Opportunities for Nanoparticle-Based Therapy, European Journal of Pharmacology (2021)
17. Pd-1 and Cancer: Molecular Mechanisms and Polymorphisms, Immunogenetics (2018)
18. Hurdles in Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
19. The Promising Role of Monoclonal Antibodies for Gastric Cancer Treatment, Immunotherapy (2019)
20. Immunotherapy a New Hope for Cancer Treatment: A Review, Pakistan Journal of Biological Sciences (2018)
21. Shedding Light on the Side Effects of Immunotherapies Used for Leukemia: An Updated Review of the Literature, Expert Review of Anticancer Therapy (2023)
22. Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons, Cell Communication and Signaling (2022)
23. Immune Checkpoint Blockade in Melanoma: Advantages, Shortcomings and Emerging Roles of the Nanoparticles, International Immunopharmacology (2022)
24. Cancer Immunology, Encyclopedia of Infection and Immunity (2022)
25. Car-T Cells: Early Successes in Blood Cancer and Challenges in Solid Tumors, Acta Pharmaceutica Sinica B (2021)
26. Current and Future Perspectives of Pd-1/Pdl-1 Blockade in Cancer Immunotherapy, Journal of Immunology Research (2021)
27. Immune Checkpoint Inhibitor (Ici) Therapy in Central Nervous System Cancers: State-Of-The-Art and Future Outlook, International Immunopharmacology (2025)
28. Targeting the Pd-1/Pd-L1 Pathway in Glioblastoma Multiforme: Preclinical Evidence and Clinical Interventions, International Immunopharmacology (2021)
29. Neurological Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy, Expert Review of Clinical Immunology (2023)
30. Pd-1/Pd-L1 Blockade: Prospectives for Immunotherapy in Cancer and Autoimmunity, IUBMB Life (2021)
31. The Current Landscape of Car T-Cell Therapy for Solid Tumors: Mechanisms, Research Progress, Challenges, and Counterstrategies, Frontiers in Immunology (2023)
32. Prospects for Chimeric Antigen Receptor (Car) Γδ T Cells: A Potential Game Changer for Adoptive T Cell Cancer Immunotherapy, Cancer Letters (2016)
33. A Metabolic Switch to Memory Car T Cells: Implications for Cancer Treatment, Cancer Letters (2021)
34. Immune Checkpoint Inhibitors in Cancer Therapy, Current Oncology (2022)
35. Construction and Functional Characterization of a Fully Human Anti-Cd19 Chimeric Antigen Receptor (Hucar)-Expressing Primary Human T Cells, Journal of Cellular Physiology (2019)
36. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
37. Applications of Innovation Technologies for Personalized Cancer Medicine: Stem Cells and Gene-Editing Tools, ACS Pharmacology and Translational Science (2023)
38. Immunopathology and Immunotherapy for Breast Cancer, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
39. Immune Checkpoints and Graves’ Disease, Thyroid Eye Disease, and Orbital Myopathy: A Comprehensive Review, Journal of Ophthalmic and Vision Research (2024)
40. Remote Controlling of Car-T Cells and Toxicity Management: Molecular Switches and Next Generation Cars, Translational Oncology (2021)
41. Tumor-Infiltrating Lymphocyte Therapy for Lung Cancer and Its Future Paradigms, Expert Opinion on Biological Therapy (2022)
42. Cell Transfer-Based Immunotherapies in Cancer: A Review, IUBMB Life (2020)
43. Immune Checkpoint Inhibition for Pancreatic Cancer, Acta Medica Iranica (2023)
44. New Approaches in Cancer Immunotherapy: Review Article, Tehran University Medical Journal (2018)
45. Monoclonal Antibodies for Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
46. Novel Car T Therapy Is a Ray of Hope in the Treatment of Seriously Ill Aml Patients, Stem Cell Research and Therapy (2021)
47. Cost‑Effectiveness Analysis of Cetuximab in Treatment of Metastatic Colorectal Cancer in Iranian Pharmaceutical Market, International Journal of Preventive Medicine (2015)
48. Chimeric Antigen Receptor -T Cell Therapy: Applications and Challenges in Treatment of Allergy and Asthma, Biomedicine and Pharmacotherapy (2020)
49. Immune Checkpoint Inhibitors for Triple-Negative Breast Cancer: From Immunological Mechanisms to Clinical Evidence, International Immunopharmacology (2021)
50. Prolonged Persistence of Chimeric Antigen Receptor (Car) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward, Frontiers in Immunology (2020)